Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E DEL-22379 colorectal adenocarcinoma sensitive detail...
FGFR2 amp RO4987655 colorectal adenocarcinoma decreased response detail...
FGFR2 amp RO5126766 colorectal adenocarcinoma predicted - sensitive detail...
FGFR2 amp Selumetinib colorectal adenocarcinoma no benefit detail...
FGFR2 - COL14A1 FGFR2 amp PRN1371 colorectal adenocarcinoma sensitive detail...
CTNNB1 S45F NTRC 0066-0 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y NTRC 0066-0 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F Mps-BAY2b colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y Mps-BAY2b colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y NMS-P715 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F NMS-P715 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1161909 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y BAY1161909 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y BAY1217389 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F BAY1217389 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F Mps1-IN-1 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y Mps1-IN-1 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y MPI-0479605 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F MPI-0479605 colorectal adenocarcinoma predicted - sensitive detail...
BRAF V600E ASTX029 colorectal adenocarcinoma sensitive detail...
ATM I1294Nfs*8 ATM E2977Rfs*2 Irinotecan + Olaparib colorectal adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00408772 Phase II Bevacizumab + Capecitabine + Oxaliplatin Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery Withdrawn USA 0
NCT00842257 Phase II Panitumumab Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer Completed USA 0
NCT01061515 Phase I Capecitabine Bevacizumab Oxaliplatin Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Active, not recruiting USA 0
NCT01079780 Phase II Cetuximab + Irinotecan + Ramucirumab Cetuximab + Irinotecan Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Completed USA 0
NCT01420874 Phase I EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Completed USA 0
NCT01442935 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Completed FRA 0
NCT01471353 Phase II Capecitabine + Sorafenib Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Completed USA 0
NCT01571284 Phase III Aflibercept + Fluorouracil + Irinotecan + Leucovorin Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed USA | ITA | ESP | DEU | CAN | BEL 17
NCT01622543 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Pelareorep Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Completed CAN 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting USA 0
NCT01652196 Phase II Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Unknown status USA 0
NCT01652482 Phase II Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA | ITA | FRA | ESP | DEU | BEL 4
NCT01802320 Phase II MK2206 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Completed USA 0
NCT01814501 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Unknown status USA 0
NCT01851369 Phase Ib/II Temozolomide + TRC102 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Recruiting USA 0
NCT01949194 Phase II Regorafenib Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Unknown status CAN 0
NCT02023333 Phase II Regorafenib Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma Active, not recruiting USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02116894 Phase I Ascrinvacumab + Regorafenib Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer Completed USA 0
NCT02149108 Phase III Nintedanib Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT02235324 Phase II Aflibercept + Fluorouracil + Leucovorin Aflibercept Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Withdrawn USA 0
NCT02248805 Phase I MGD007 Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma Completed USA 0
NCT02292758 Phase II Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer Completed USA 0
NCT02368886 Phase II Clobetasol + Regorafenib Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02375672 Phase II Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Completed USA 0
NCT02413853 Phase II Bevacizumab PRI-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer Withdrawn USA 0
NCT02466009 Phase II Regorafenib Regorafenib in Metastatic Colorectal Cancer Completed USA 0
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Active, not recruiting USA | ESP | DEU | BEL | AUT 4
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed USA 0
NCT02602327 Phase I Trifluridine-tipiracil hydrochloride Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases Completed USA 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02651415 Phase II Perindopril + Regorafenib Phase II Study of Perindopril and Regorafenib in mCRC Completed CAN 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Recruiting USA 1
NCT02780700 Phase II Capecitabine + Nintedanib Nintedanib Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] Terminated USA 0
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed USA 0
NCT02860546 Phase II Nivolumab + Trifluridine-tipiracil hydrochloride A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Completed USA 0
NCT02876224 Phase I Atezolizumab + Bevacizumab + Cobimetinib Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Completed USA | ESP 0
NCT02885753 Phase III Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) Recruiting FRA 1
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Terminated USA 1
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed USA 0
NCT03069950 Phase II Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Withdrawn USA 0
NCT03081494 Phase I Regorafenib + Spartalizumab Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer Completed ITA | ESP | CAN 5
NCT03087071 Phase II Panitumumab Panitumumab + Trametinib Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Recruiting USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Active, not recruiting USA 0
NCT03104439 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting USA 0
NCT03117972 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) Recruiting FRA 0
NCT03186326 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) Active, not recruiting FRA 0
NCT03192345 Phase I Cemiplimab + SAR439459 SAR439459 A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 6
NCT03258398 Phase II Avelumab + Tomivosertib Tomivosertib A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer Completed USA 0
NCT03277209 Phase I Plerixafor To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Terminated USA 1
NCT03300609 Phase III Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Terminated USA 0
NCT03332498 Phase Ib/II Ibrutinib + Pembrolizumab Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers Completed USA 0
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + MM-398 + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting USA 0
NCT03366155 Phase II Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver Recruiting USA 0
NCT03368963 Phase Ib/II MM-398 + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03373188 Phase I Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Active, not recruiting USA 0
NCT03376659 Phase Ib/II Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Active, not recruiting USA 0
NCT03377361 Phase Ib/II Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9) Recruiting USA | ITA | ESP | DEU | CAN | BEL 6
NCT03384940 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) Completed USA | ITA | ESP 2
NCT03396926 Phase II Bevacizumab + Capecitabine + Pembrolizumab Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03436563 Phase Ib/II M7824 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Active, not recruiting USA 0
NCT03442569 Phase II Ipilimumab + Nivolumab + Panitumumab PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Active, not recruiting USA 0
NCT03475004 Phase II Bevacizumab + Binimetinib + Pembrolizumab Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Active, not recruiting USA 0
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Recruiting USA 0
NCT03542877 Phase II Cabozantinib Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer Completed USA 0
NCT03576963 Phase Ib/II Guadecitabine + Nivolumab Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer Withdrawn USA 0
NCT03597581 Phase I RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202 A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies Recruiting USA 0
NCT03608046 Phase II Avelumab + Cetuximab + Irinotecan Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI) Recruiting BEL 0
NCT03610490 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT03626922 Phase I Folic Acid Cyanocobalamin Oxaliplatin + Pembrolizumab + Pemetrexed Disodium Dexamethasone Pembrolizumab + Pemetrexed Disodium Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients Active, not recruiting USA 0
NCT03642067 Phase II Nivolumab + Relatlimab Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA 5
NCT03712943 Phase I Nivolumab + Regorafenib Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer Active, not recruiting USA 0
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA | FRA | ESP 3
NCT03750786 Phase III Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT) Active, not recruiting USA | FRA | ESP | DEU | CAN | AUT 4
NCT03800602 Phase II Metformin + Nivolumab Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Active, not recruiting USA 0
NCT03828227 Phase III Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) Recruiting FRA 0
NCT03874026 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA) Recruiting ITA 0
NCT04054752 Phase I NT-I7 Vaccine Response With NT-I7 Recruiting USA 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA 1
NCT04094688 Phase III Bevacizumab + Cholecalciferol + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Cholecalciferol + Fluorouracil + Irinotecan + Leucovorin Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS) Recruiting USA 1
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Recruiting USA 0
NCT04117945 Phase II Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Recruiting USA 0
NCT04119830 Phase II Pembrolizumab + Rintatolimod Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer Withdrawn USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Recruiting USA | ESP | DEU 2
NCT04166435 Phase II Olaparib + Temozolomide TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer Active, not recruiting USA 0
NCT04171141 Phase I PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Recruiting USA 2
NCT04188145 Phase III Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) Recruiting FRA 0
NCT04214418 Phase Ib/II Atezolizumab + Cobimetinib + Hydroxychloroquine Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) Recruiting USA 0
NCT04262687 Phase II Bevacizumab + Capecitabine + Oxaliplatin + Pembrolizumab Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) Recruiting FRA 0
NCT04310176 Phase II Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) Recruiting ITA 0
NCT04322539 Phase III Fruquintinib A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer (FRESCO-2) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Recruiting USA 1
NCT04456699 Phase III Bevacizumab + Olaparib Bevacizumab + Fluorouracil Olaparib Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU) Active, not recruiting USA | FRA | ESP | DEU | CAN | BEL 12
NCT04457284 Phase II Cisplatin + Nivolumab + Temozolomide Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer Recruiting USA 0
NCT04474470 Phase Ib/II Cetuximab + NT219 NT219 A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Recruiting USA 0
NCT04491955 Phase II ALT-803 + CV301 + M7824 + NHS-IL12 ALT-803 + CV301 + M7824 Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers Recruiting USA 0
NCT04513951 Phase II Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) Active, not recruiting ITA 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) Recruiting USA 0
NCT04575922 Phase II Ipilimumab + Nivolumab Nivolumab+Ipilimumab+RT in MSS mCRC Recruiting USA 0
NCT04660812 Phase Ib/II AB680 + AB928 + Zimberelimab Regorafenib AB928 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB928 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. Recruiting USA | ITA | FRA | ESP | DEU 2
NCT04689347 Phase I Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. Recruiting ITA 0
NCT04729322 Phase I Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders Recruiting USA 0
NCT04730544 Phase II Ipilimumab + Nivolumab Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer (NIPISAFE) Recruiting FRA 0
NCT04731467 Phase Ib/II CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Recruiting USA 1
NCT04744831 Phase II Trastuzumab deruxtecan Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) Active, not recruiting USA | ITA | FRA | ESP | BEL 5
NCT04776148 Phase III Regorafenib Trifluridine-tipiracil hydrochloride Lenvatinib + Pembrolizumab Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Active, not recruiting USA | ESP | DEU | CAN 11
NCT04776655 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) Recruiting ITA 0
NCT04853043 Phase II Cetuximab Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer Recruiting USA 0
NCT04868773 Phase I Cabozantinib + Trifluridine-tipiracil hydrochloride Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Recruiting USA 0
NCT04873895 Phase I Axitinib + Hydroxychloroquine TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) (TACE-Ax-HCQ) Recruiting USA 0
NCT04895722 Phase II MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 5
NCT04952753 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) Recruiting USA | FRA | ESP | DEU 7
NCT04963283 Phase II Cabozantinib + Nivolumab A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Recruiting USA 0
NCT05064059 Phase III Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Recruiting USA | ITA | FRA | ESP | DEU | CAN 15
NCT05087992 Phase I Bevacizumab + BI 905711 + Fluorouracil + Irinotecan + Leucovorin BI 905711 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers Recruiting USA | BEL 2
NCT05121038 Phase Ib/II CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) Recruiting USA 0
NCT05130060 Phase I PolyPEPI1018 + Trifluridine-tipiracil hydrochloride A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer Recruiting USA 0
NCT05198934 Phase III Regorafenib + Trifluridine-tipiracil hydrochloride Panitumumab + Sotorasib Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300) Recruiting USA | ITA | FRA | ESP | DEU 5
NCT05200442 Phase Ib/II Cetuximab + RO5126766 A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer Not yet recruiting USA 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Recruiting USA 0
NCT05223673 Phase III Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) Recruiting USA | BEL 3
NCT05253651 Phase III Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Recruiting USA 0
NCT05286814 Phase II Fluorouracil + Leucovorin + NHS-IL12 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NHS-IL12 M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Not yet recruiting USA 0
NCT05291156 Phase II Cetuximab Avelumab + Cetuximab CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy Not yet recruiting ITA 0
NCT05310643 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) Recruiting FRA 0
NCT05312398 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen Recruiting ITA 0
NCT05328908 Phase III Regorafenib + Trifluridine-tipiracil hydrochloride nivolumab and relatlimab-rmbw A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 14
NCT05330429 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) Recruiting USA 1
NCT05382741 Phase II Durvalumab + Regorafenib Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA) Recruiting ITA 0